Michael A. Schwarzschild, M.D., Ph.D.
This page shows the publications co-authored by Michael Schwarzschild and Sabrina Paganoni.
Urate as a Marker of Risk and Progression of Neurodegenerative Disease. Neurotherapeutics. 2017 01; 14(1):148-153.
Pilot trial of inosine to elevate urate levels in amyotrophic lateral sclerosis. Ann Clin Transl Neurol. 2018 Dec; 5(12):1522-1533.
Urate mitigates oxidative stress and motor neuron toxicity of astrocytes derived from ALS-linked SOD1G93A mutant mice. Mol Cell Neurosci. 2018 10; 92:12-16.
Prediagnostic Neurofilament Light Chain Levels in Amyotrophic Lateral Sclerosis. Neurology. 2021 Aug 11.
Imaging Neurochemistry and Brain Structure Tracks Clinical Decline and Mechanisms of ALS in Patients. Front Neurol. 2020; 11:590573.
Pre-diagnostic plasma lipid levels and the risk of amyotrophic lateral sclerosis. Amyotroph Lateral Scler Frontotemporal Degener. 2021 02; 22(1-2):133-143.
Prediagnostic plasma metabolomics and the risk of amyotrophic lateral sclerosis. Neurology. 2019 04 30; 92(18):e2089-e2100.
Prediagnostic plasma branched-chain amino acids and the risk of amyotrophic lateral sclerosis. Neurology. 2019 04 30; 92(18):e2081-e2088.
Serum urate at trial entry and ALS progression in EMPOWER. Amyotroph Lateral Scler Frontotemporal Degener. 2017 02; 18(1-2):120-125.
The connection strength for co-authors is the sum of the scores for each of their shared publications.
Publication scores are based on many factors, including how long ago they were written and whether the person is a first or senior author.